TY - JOUR

T1 - Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy

T2 - A Randomized Controlled Trial (SUPER)

AU - Skougaard, Kristin

AU - Østrup, Olga

AU - Guldbrandsen, Kasper

AU - Sørensen, Boe

AU - Meldgaard, Peter

AU - Saghir, Zaigham

AU - Gørtz, Peter

AU - Lonsdale, Markus Nowak

AU - Frank, Malene Støchkel

AU - Gerke, Oke

AU - Rychwicka-Kielek, Beata Agnieszka

AU - Persson, Gitte

AU - Land, Lotte Holm

AU - Schytte, Tine

AU - Bodtger, Uffe

AU - Skuladottir, Halla

AU - Søgaard, Jes

AU - Nielsen, Søren Steen

AU - Rasmussen, Torben Riis

AU - Fischer, Barbara Malene

PY - 2020

Y1 - 2020

N2 - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

AB - Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

U2 - 10.1016/j.cllc.2019.11.002

DO - 10.1016/j.cllc.2019.11.002

M3 - Journal article

C2 - 31839533

VL - 21

SP - e61-e64

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -